J. Goldman & Co’s Seres Therapeutics MCRB Stock Holding History

J. Goldman & Co’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,000	Closed	-$519K	–	665
2025 Q3	$519K	Buy	+27,000	New	+$431K	0.01%	376

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

J. Goldman & Co's MCRB Position: Q4 2025 in Review

J. Goldman & Co sold out of Seres Therapeutics (MCRB) in Q4 2025, closing a stake of 27,000 shares — an estimated $519K sold.

J. Goldman & Co first reported a position in MCRB in Q3 2025 and held it in 1 quarter. The position peaked at $519K in Q3 2025. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

J. Goldman & Co reported no remaining Seres Therapeutics position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 27,000 Seres Therapeutics shares in Q4 2025, an estimated $519K.
J. Goldman & Co first reported a position in Seres Therapeutics in Q3 2025 and held it in 1 quarter.
J. Goldman & Co's Seres Therapeutics position peaked at $519K in Q3 2025.
36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.